Integrating Companion Diagnostics into Precision Oncology Trials

What Are Companion Diagnostics and Why They Matter

Companion diagnostics (CDx) are in vitro diagnostic devices or imaging tools essential for the safe and effective use of a corresponding therapeutic product. In oncology, CDx testing is often the gateway to trial enrollment—patients must meet specific biomarker-defined eligibility criteria before receiving the investigational drug. For example, a HER2-targeted therapy requires HER2 amplification confirmation, an EGFR inhibitor needs exon 19 deletions or L858R mutations, and an ALK inhibitor demands ALK rearrangement detection.

The role of CDx is not only to identify patients most likely to benefit but also to exclude those at higher risk of adverse effects. Regulators like the FDA and EMA mandate that, when biomarker-based eligibility is critical, the diagnostic must be validated to the same standard of evidence as the drug itself. This concept is central to precision oncology: the therapy’s approval can be contingent on having an approved CDx available.

Real-world example: Trastuzumab deruxtecan was approved alongside a specific HER2 testing method with defined scoring cutoffs. Without an approved HER2 IHC or ISH assay, trial enrollment would not have been possible. Similarly, osimertinib’s label specifies that only EGFR T790M-positive patients by an FDA-approved test are eligible post-EGFR-TKI resistance.

Regulatory Expectations: FDA, EMA, and Global Considerations

From a regulatory standpoint, companion diagnostics are considered high-risk (Class III in the US, Class C under IVDR in the EU) because incorrect results can lead to inappropriate treatment. The FDA’s guidance “In Vitro Companion Diagnostic Devices” specifies that CDx must demonstrate both analytical and clinical validation. Analytical validation ensures that the assay reliably and reproducibly measures the biomarker; clinical validation confirms the biomarker’s predictive value in identifying patients who will benefit from the therapy.

In the EU, under the IVDR (Regulation (EU) 2017/746), companion diagnostics must be assessed by a notified body and involve consultation with a competent medicines authority, such as the EMA. This adds complexity and timelines, especially for global oncology trials seeking simultaneous approval in multiple jurisdictions. Countries like Japan, China, and Australia have their own specific regulatory frameworks, and harmonizing CDx approvals can be a major operational challenge.

One frequent pitfall in global trials is assuming that a US-approved CDx automatically meets EU or APAC requirements—it often does not. This requires early regulatory strategy alignment between drug and diagnostic development teams, ideally before pivotal trial protocol finalization.

Analytical Validation: Establishing Assay Performance (LOD, LOQ, and More)

Analytical validation parameters for CDx include sensitivity, specificity, limit of detection (LOD), limit of quantitation (LOQ), reproducibility, and robustness. For example, a ctDNA-based assay for detecting EGFR T790M may need an LOD of 0.2% variant allele frequency (VAF) with ≥95% confidence to ensure that eligible patients are not missed. LOQ might be set at 0.5% VAF to ensure reliable quantitation for therapy decision-making.

For cross-contamination risk in diagnostic reagent preparation, applying pharmaceutical cleaning validation concepts like MACO (Maximum Allowable Carryover) and PDE (Permitted Daily Exposure) ensures that no assay-to-assay contamination occurs in multi-test platforms.

Designing Clinical Trials with Companion Diagnostics

When integrating CDx into oncology trials, trial design must reflect the biomarker’s prevalence, predictive power, and the assay’s availability. In an enrichment design, only biomarker-positive patients are enrolled, maximizing effect size but potentially slowing accrual if prevalence is low. An all-comers design with biomarker-stratified analysis allows exploratory evaluation of biomarker-negative patients.

Adaptive designs can allow for mid-trial modifications based on interim biomarker prevalence data, while basket and umbrella trials can leverage a single assay to assign patients to multiple targeted therapies. For example, a comprehensive NGS panel could identify HER2 amplification, BRAF mutations, and RET fusions for allocation to different arms within the same master protocol.

Operationalizing CDx Testing in Trials

Operational success depends on fast turnaround times (TAT) and consistent assay performance across global sites. Establishing a central testing laboratory can standardize results but may increase logistical complexity for sample shipment. Alternatively, a decentralized model with harmonized local labs requires rigorous cross-validation (≥90% concordance with central lab results).

Consent forms must explicitly mention the use of a companion diagnostic, potential incidental findings (e.g., germline BRCA mutations), and data sharing for regulatory purposes. Clinical trial management systems should track test performance metrics, including invalid rates, re-testing frequency, and median TAT.

Reference operational SOPs, such as those available on PharmaGMP.in, to streamline documentation for audits and inspections.

Regulatory Submission and Approval Pathways

The drug and the CDx are often submitted concurrently in a coordinated regulatory package. The FDA requires a premarket approval (PMA) for most CDx devices, while the EMA mandates a CE marking under IVDR rules. Bridging studies may be required if the pivotal trial assay differs from the commercial version, with statistical comparability set at ≥90% concordance.

Post-approval, CDx manufacturers may need to expand the assay’s indications, such as adding ctDNA detection to a tissue-based test. These modifications typically require supplemental PMA submissions or revised technical documentation under IVDR.

Conclusion: Making CDx Work for Precision Oncology

Effective companion diagnostics require early and integrated planning between drug and diagnostic development teams. By aligning regulatory strategies, ensuring rigorous analytical validation, and building operational workflows that can deliver results rapidly and reproducibly, CDx can significantly increase the probability of trial success and regulatory approval. The reward is a therapy that reaches the right patients faster, with robust evidence that the biomarker truly guides treatment benefit.

Navigating Global Regulations for Companion Diagnostics

Introduction: The International Landscape of Companion Diagnostics

As precision medicine expands globally, the co-development and approval of companion diagnostics (CDx) has become a critical component of regulatory strategy for both pharmaceutical and diagnostic developers. Companion diagnostics guide the safe and effective use of corresponding drugs, and regulators across the world have established specific frameworks to manage their approval and post-market lifecycle.

This tutorial explores the regulatory expectations across major regions—United States, Europe, Japan, China, Canada, India, and others. Understanding these global frameworks is essential for aligning submission strategies, reducing delays, and achieving concurrent drug-diagnostic approvals.

United States: FDA Regulatory Framework

The U.S. Food and Drug Administration (FDA) regulates companion diagnostics as Class III medical devices. CDx must undergo a Premarket Approval (PMA) process and are reviewed by the Center for Devices and Radiological Health (CDRH) in collaboration with CDER or CBER for the therapeutic product.

• FDA requires CDx to be approved, cleared, or authorized before the associated drug can be marketed.
• Validation data must support both analytical and clinical performance.
• CDx must be referenced in the drug labeling and vice versa.

Key documents:

• FDA Guidance on In Vitro Companion Diagnostic Devices
• 21 CFR Part 814 (PMA requirements)

IDE approval is also necessary for investigational use in pivotal clinical trials.

European Union: EMA and IVDR

In Europe, companion diagnostics are regulated under the In Vitro Diagnostic Regulation (EU IVDR 2017/746), which came into effect in May 2022. Under IVDR, CDx are classified as Class C IVDs and require involvement of a Notified Body and consultation with the European Medicines Agency (EMA).

Key requirements include:

• Performance evaluation (analytical, clinical, and scientific validity)
• EU Declaration of Conformity and CE marking
• EMA consultation for the companion drug

For instance, a CDx co-developed for a targeted cancer therapy must submit both a performance evaluation report and a summary of safety and performance (SSP).

Read EMA diagnostic consultation procedures at EMA.

Japan: PMDA and MHLW

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) evaluates companion diagnostics, with final approval granted by the Ministry of Health, Labour and Welfare (MHLW). Japan requires simultaneous review of the drug and diagnostic.

• CDx must be filed as “Designated Medical Devices.”
• Consultation with PMDA is mandatory before formal submission.
• Japanese translation and local clinical data are often required.

Timeline optimization in Japan requires strategic pre-submission dialogue, known as “prior assessment consultation.”

China: NMPA/CDx Oversight

China’s National Medical Products Administration (NMPA), formerly CFDA, requires CDx to be approved concurrently with the therapeutic product. NMPA’s regulation is evolving rapidly to align with global norms.

Notable requirements:

• Companion diagnostics must be listed in the drug label.
• Local clinical trials or bridging studies often mandated.
• Product registration classified as Class III for CDx.

NMPA recently emphasized the importance of “coordinated submissions” to support joint approval pathways.

India: CDSCO and Diagnostic Rules

India’s Central Drugs Standard Control Organization (CDSCO) regulates IVDs, including companion diagnostics, under the Medical Devices Rules (2017). CDx are categorized as Class C or D devices and require a detailed registration dossier and Form MD-14 application.

• Local agent or authorized representative is required for foreign manufacturers.
• Clinical performance evaluation may be required unless waived.
• Labeling and shelf-life studies are emphasized by CDSCO.

India also aligns with ISO 13485:2016 and requires local registration for import, as per GSR 102(E).

Detailed application forms and templates are available at PharmaSOP.in.

Canada: Health Canada Guidance

Health Canada regulates CDx under its Medical Devices Regulations. A CDx is considered a Class III device and must be approved before the associated drug is authorized under a Notice of Compliance (NOC).

• Submission requires Device License Application and evidence of effectiveness.
• Simultaneous or staggered drug-diagnostic approvals are possible.
• Companion diagnostics must be referenced in drug labeling.

Post-market requirements include annual license renewal and complaint handling procedures under ISO 13485.

Other Global Regulatory Pathways

Australia (TGA): CDx are classified as Class 3 IVDs, and registration requires conformity assessment certification or recognition under MDSAP (Medical Device Single Audit Program).

Brazil (ANVISA): CDx are regulated as “Type III Risk Devices.” ANVISA requires a Registro application with analytical and clinical performance data, often in Portuguese.

South Korea (MFDS): Companion diagnostics fall under the Medical Device Act and must undergo KFDA evaluation with mandatory Korean translation and local agent representation.

Russia: CDx approval involves the Roszdravnadzor and requires a Clinical Trials of Medical Devices (CTMD) permit. Localization and language compliance are essential.

Common Submission Elements Across Regions

Despite regional variations, most CDx submissions must include:

• Analytical validation (LOD, LOQ, specificity)
• Clinical performance linked to drug efficacy
• Risk classification and intended use
• Manufacturing and quality control data
• Labeling and IFU in local language

Dummy Table: Common Parameters Required

Harmonization Efforts and Industry Best Practices

Regulators and industry groups have launched harmonization initiatives to reduce regulatory duplication and facilitate concurrent approvals:

• International Medical Device Regulators Forum (IMDRF)
• ICH guidelines for diagnostics
• CDRH’s Case for Quality and Total Product Life Cycle (TPLC) programs

Best practices include using global dossier formats, aligning drug and diagnostic development timelines, and planning regulatory consultations early in development.

Visit FDA or ICH for more harmonization resources.

Conclusion

Companion diagnostics operate in a highly regulated global environment. Successfully navigating these frameworks requires a thorough understanding of each country’s unique requirements, strategic planning, and early alignment with therapeutic development. With global harmonization gaining traction, sponsors can increasingly streamline submissions and achieve faster access to markets worldwide—delivering on the promise of personalized healthcare.